See more : EXEDY Corporation (7278.T) Income Statement Analysis – Financial Results
Complete financial analysis of bioAffinity Technologies, Inc. (BIAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of bioAffinity Technologies, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Cipher Mining Inc. (CIFR) Income Statement Analysis – Financial Results
- Vine Hill Capital Investment Corp. Unit (VCICU) Income Statement Analysis – Financial Results
- BSF Enterprise Plc (BSFA.L) Income Statement Analysis – Financial Results
- Selan Exploration Technology Limited (SELAN.BO) Income Statement Analysis – Financial Results
- Sizzle Acquisition Corp. (SZZL) Income Statement Analysis – Financial Results
bioAffinity Technologies, Inc. (BIAF)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.bioaffinitytech.com
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.53M | 4.80K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 467.00 | 4.82K | 22.24K | 40.28K |
| Gross Profit | 791.62K | 4.34K | -4.82K | -22.24K | -40.28K |
| Gross Profit Ratio | 31.26% | 90.28% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.72M | 1.29M | 1.33M | 1.61M | 1.85M |
| General & Administrative | 0.00 | 2.73M | 880.77K | 994.34K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.79M | 2.73M | 880.77K | 994.34K | 1.20M |
| Other Expenses | 249.59K | -1.87M | 724.93K | -4.28M | 0.00 |
| Operating Expenses | 8.76M | 4.02M | 2.21M | 2.60M | 3.05M |
| Cost & Expenses | 10.51M | 4.02M | 2.21M | 2.60M | 3.09M |
| Interest Income | 122.13K | 46.71K | 424.00 | 1.07K | 2.78K |
| Interest Expense | 37.13K | 2.53M | 1.00M | 382.17K | 214.83K |
| Depreciation & Amortization | 249.59K | 10.18K | 4.82K | 22.24K | 40.28K |
| EBITDA | -7.63M | -5.61M | -2.20M | -6.86M | -3.05M |
| EBITDA Ratio | -301.26% | -121,196.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.97M | -4.01M | -2.21M | -2.60M | -3.09M |
| Operating Income Ratio | -314.84% | -83,511.51% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 57.21K | -4.14M | -4.12M | -4.66M | -212.06K |
| Income Before Tax | -7.92M | -8.15M | -6.32M | -7.27M | -3.30M |
| Income Before Tax Ratio | -312.58% | -169,720.05% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 20.99K | 2.46K | 1.95K | 2.75K | 3.20K |
| Net Income | -7.94M | -8.15M | -6.33M | -7.27M | -3.31M |
| Net Income Ratio | -313.41% | -169,771.25% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -1.81 | -0.86 | -0.99 | -0.45 |
| EPS Diluted | -0.91 | -1.81 | -0.86 | -0.99 | -0.45 |
| Weighted Avg Shares Out | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
| Weighted Avg Shares Out (Dil) | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents at Dawson James Small Cap Growth Conference this week.
bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity President and CEO Maria Zannes will present at H.C. Wainwright Global Investment Conference Sept. 11-13.
bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports second quarter 2023 financial results and provides business update.
AMA Issues CPT Code for bioAffinity Technologies' CyPath® Lung Test for Early-Stage Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #AMA--The AMA has issued a CPT code specifically for bioAffinity Technologies' CyPath® Lung noninvasive test for early-stage lung cancer.
bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment, today reported its financial results for the third quarter of 2022...
bioAffinity Technologies to Report Third Quarter 2022 Financial Results
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced that the Company will host a conference call and audio webcast on Monday, Nov. 14, 2022, at 8 a.m.
Stock Market Today: What Happened & 3 Penny Stocks To Watch Now
What happened in the stock market today and Penny stocks to watch this week. The post Stock Market Today: What Happened & 3 Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information |...
7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up
Penny sleeper stocks can offer tremendous risks to investors. However, much like any other speculative investment category, it's possible that traders can still generate incredible, perhaps life changing profits.
Penny Stocks to Buy in a Bear Market? 3 to Watch Right Now
Are these penny stocks on your watchlist today? The post Penny Stocks to Buy in a Bear Market?
Why Is BioAffinity (BIAF) Stock Up 40% Today?
Early diagnosis specialist BioAffinity (NASDAQ: BIAF ) spiked 60% on Wednesday morning before paring back some gains in the afternoon to around 40% up. Investors piled into BIAF stock upon the underlying company disclosing the receipt of approximately $7.7 million...
Source: https://incomestatements.info
Category: Stock Reports